Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer

Journal of International Medical Research

Volumn 43, Issue 2, 2015, Pages 173-179

  Wu, Xiao Jin ^a,b   Li, Xiao Dong ^c   Zhang, Hanze ^d   Zhang, Xiaofei ^e   Ning, Zhong Hua ^c   Yin, Yong Mei ^f   Tian, Ye ^a  

^a THE SECOND AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b First People's Hospital of Xuzhou   (China)

^c THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e TOHOKU UNIVERSITY   (Japan)

^f THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

adhesion molecule; Breast cancer; CD44; clinical significance; immunohistochemistry

Indexed keywords

ANTIGEN; CD44V3 ANTIGEN; CD44V6 ANTIGEN; FORMALDEHYDE; HERMES ANTIGEN; PARAFFIN; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; ISOPROTEIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; TUMOR VOLUME; BREAST TUMOR; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD44; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MIDDLE AGED; PROTEIN ISOFORMS; TUMOR BURDEN;

EID: 84924959182     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060514559793     Document Type: Article

References (25)

1. Ferlay J,Shin HR,Bray F, et al.Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.Int J Cancer. 2010;127:2893-2917
2. Naor D,Sionov RV,Ish-Shalom D.CD44: structure, function, and association with the malignant process.Adv Cancer Res. 1997;71:241-319
3. Perez A,Neskey DM,Wen J, et al.CD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progression.Oral Oncol. 2013;49:306-313
4. Franzmann EJ,Reategui EP,Pedroso F, et al.Soluble CD44 is a potential marker for the early detection of head and neck cancer.Cancer Epidemiol Biomarkers Prev. 2007;16:1348-1355
5. Watanabe O,Kinoshita J,Shimizu T, et al.Expression of a CD44 variant and VEGF-C and the implications for lymphatic metastasis and long-term prognosis of human breast cancer.J Exp Clin Cancer Res. 2005;24:75-82
6. Anand MT,Kumar S.CD44: A key player in breast cancer.Indian J Cancer. 2014;51:247-250
7. Afify A,Purnell P,Nguyen L.Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.Exp Mol Pathol. 2009;86:95-100
8. Liu YJ,Yan PS,Li J, et al.Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.World J Gastroenterol. 2005;11:6601-6606
9. Gong Y,Sun X,Huo L, et al.Expression of cell adhesion molecules, CD44s and E-cadherin, and microvessel density in invasive micropapillary carcinoma of the breast.Histopathology. 2005;46:24-30
10. Ryś J,Kruczak A,Lackowska B, et al.The role of CD44v3 expression in female breast carcinomas.Pol J Pathol. 2003;54:243-247
11. Franzmann EJ,Weed DT,Civantos FJ, et al.A novel CD44 v3 isoform is involved in head and neck squamous cell carcinoma progression.Otolaryngol Head Neck Surg. 2001;124:426-432
12. Tempfer C,Sliutz G,Haeusler G, et al.CD44v3 and v6 variant isoform expression correlates with poor prognosis in early-stage vulvar cancer.Br J Cancer. 1998;78:1091-1094
13. Gunthert U,Hofmann M,Rudy W, et al.A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells.Cell. 1991;65:13-24
14. Kaufmann M,Heider KH,Sinn HP, et al.CD44 variant exon epitopes in primary breast cancer and length of survival.Lancet. 1995;345:615-619
15. Mayer B,Jauch KW,Gunthert U, et al.De-novo expression of CD44 and survival in gastric cancer.Lancet. 1993;342:1019-1022
16. Ropponen KM,Eskelinen MJ,Lipponen PK, et al.Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.Scand J Gastroenterol. 1998;33:301-309
17. Shi J,Zhou Z,Di W, et al.Correlation of CD44v6 expression with ovarian cancer progression and recurrence.BMC Cancer. 2013;13:182-182
18. Omran OM,Ata HS.CD44s and CD44v6 in diagnosis and prognosis of human bladder cancer.Ultrastruct Pathol. 2012;36:145-152
19. Coradini D,Zorzet S,Rossin R, et al.Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But.Clin Cancer Res. 2004;10:4822-4830
20. AJCC Cancer Staging Manual. 7th edn. Chapter 32. Berlin, Germany: Springer, 2010.Chapter 32. Berlin, Germany: Springer; 2010:
21. Kopp R,Classen S,Wolf H, et al.Predictive relevance of soluble CD44v6 serum levels for the responsiveness to second line hormone- or chemotherapy in patients with metastatic breast cancer.Anticancer Res. 2001;21:2995-3000
22. Bendardaf R,Algars A,Elzagheid A, et al.Comparison of CD44 expression in primary tumours and metastases of colorectal cancer.Oncol Rep. 2006;16:741-746
23. Arch R,Wirth K,Hofmann M, et al.Participation in normal immune responses of a metastasis-inducing splice variant of CD44.Science. 1992;257:682-685
24. Lokeshwar VB,Iida N,Bourguignon LY.The cell adhesion molecule, GP116, is a new CD44 variant (ex14/v10) involved in hyaluronic acid binding and endothelial cell proliferation.J Biol Chem. 1996;271:23853-23864
25. Ponta H,Sherman L,Herrlich PA.CD44: from adhesion molecules to signalling regulators.Nat Rev Mol Cell Biol. 2003;4:33-45